新型订书肽MDM2/X-p53拮抗剂PM2增强177Lu标记抗CD44v6抗体AbN44v6对三维多细胞肿瘤球体的体外靶向放射核素治疗效应
本研究在两种野生型p53细胞系(HCT116结直肠癌与UM-SCC-74B头颈鳞癌)来源的三维多细胞肿瘤球体中,评估了新型订书肽MDM2/X-p53拮抗剂PM2对177Lu标记抗CD44v6抗体AbN44v6靶向放射核素治疗(TRNT)的增效作用。结果显示177Lu-AbN44v6以剂量依赖和抗原依赖方式抑制球体生长,20 μM PM2单药即显著抑制球体生长,两者联合比任一单药均显著更强。
要点
- 177Lu-AbN44v6以剂量依赖和抗原依赖方式抑制两种细胞系球体生长。
- 20 μM PM2单药显著抑制两种球体模型生长。
- TRNT联合PM2比任一单药显著更强,HCT116球体联合组生长速率较单药降低两至三倍。
核心结论
- 177Lu-AbN44v6的TRNT以剂量依赖和抗原依赖方式有效抑制球体生长,PM2单药具有生长抑制作用。
- TRNT与PM2联合在三维多细胞肿瘤球体模型中增强了TRNT的治疗效应,该概念验证研究展示了靶向CD44v6的TRNT与PM2联合的潜力与可能性。
研究设计与样本
- 体外研究,使用两种野生型p53细胞系:HCT116(结直肠癌)和UM-SCC-74B(头颈鳞状细胞癌),表达不同水平的靶抗原CD44v6。
- 先在二维细胞实验中验证177Lu-AbN44v6的抗原特异性结合,再用蛋白质印迹评估未标记AbN44v6对Erk1/2下游磷酸化的影响。
- 在三维多细胞肿瘤球体实验中评估未标记AbN44v6、177Lu-AbN44v6、PM2或联合(标记/未标记AbN44v6±PM2)的治疗效果。
主要发现
- 放射性标记抗体在两种细胞系上均特异性结合CD44v6。
- 未标记AbN44v6在所有测试浓度下均未诱导Erk1/2下游磷酸化,重复使用未标记抗体未导致任何球体生长抑制。
- 177Lu-AbN44v6以剂量依赖和抗原依赖方式损害球体生长。
- 20 μM PM2单药显著损害两种球体模型的球体生长。
- TRNT与PM2联合比任一单药显著更强;HCT116球体中,PM2联合100 kBq 177Lu-AbN44v6在治疗后14天较单药使球体生长速率降低两至三倍;UM-SCC-74B球体中,联合治疗在治疗后10天使球体尺寸较初始尺寸缩小。
关键数值与推荐
- 未标记AbN44v6在所有测试浓度下均未诱导Erk1/2下游磷酸化,重复治疗未导致球体生长抑制。
- PM2单药剂量为20 μM时显著损害两种球体模型生长。
- HCT116球体中,PM2联合100 kBq 177Lu-AbN44v6在治疗后14天较单药使球体生长速率降低两至三倍。
- UM-SCC-74B球体中,联合治疗在治疗后10天使球体尺寸较初始尺寸缩小。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Precision therapeutics continuously make advances in cancer therapy, and a field of growing interest is the combination of targeted radionuclide therapy (TRNT) with potential radiosensitizing agents. This study evaluated whether the effects of in vitro TRNT, using the 177Lu-labeled anti-CD44v6 antibody AbN44v6, were potentiated by the novel stapled MDM2/X-p53 antagonist PM2. MATERIALS AND METHODS: Two wt p53 cell lines, HCT116 (colorectal carcinoma) and UM-SCC-74B (head and neck squamous cell carcinoma), expressing different levels of the target antigen, CD44v6, were used. Antigen-specific binding of 177Lu-AbN44v6 was initially verified in a 2D cell assay, after which the potential effects of unlabeled AbN44v6 on downstream phosphorylation of Erk1/2 were evaluated by western blotting. Further, the therapeutic effects of unlabeled AbN44v6, 177Lu-AbN44v6, PM2, or a combination (labeled/unlabeled AbN44v6 +/- PM2) were assessed in 3D multicellular tumor spheroid assays. RESULTS: Radiolabeled antibody bound specifically to CD44v6 on both cell lines. Unlabeled AbN44v6 binding did not induce downstream phosphorylation of Erk1/2 at any of the concentrations tested, and repeated treatments with the unlabeled antibody did not result in any spheroid growth inhibition. 177Lu-AbN44v6 impaired spheroid growth in a dose-dependent and antigen-dependent manner. A single modality treatment with 20 μM of PM2 significantly impaired spheroid growth in both spheroid models. Furthermore, the combination of TRNT and PM2-based therapy proved significantly more potent than either monotherapy. In HCT116 spheroids, this resulted in a two- and threefold spheroid growth rate decrease for the combination of PM2 and 100 kBq 177Lu-AbN44v6 compared to monotherapies 14-day post treatment. In UM-SCC-74B spheroids, the combination therapy resulted in a reduction in spheroid size compared to the initial spheroid size 10-day post treatment. CONCLUSION: TRNT using 177Lu-AbN44v6 proved efficient in stalling spheroid growth in a dose-dependent and antigen-dependent manner, and PM2 treatment demonstrated a growth inhibitory effect as a monotherapy. Moreover, by combining TRNT with PM2-based therapy, therapeutic effects of TRNT were potentiated in a 3D multicellular tumor spheroid model. This proof-of-concept study exemplifies the strength and possibility of combining TRNT targeting CD44v6 with PM2-based therapy.
引用
- Mortensen ACL, Morin E, Brown CJ, et al. Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2. EJNMMI Res. 2020. PMID: 32300907. doi:10.1186/s13550-020-0613-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。